Coventry, UK, 7th March 2018 / Sciad NewswireMedherant Ltd, a leader in next-generation transdermal drug delivery, is pleased to announce the appointment of a new senior executive, David Davies, as Head of Development. This appointment marks a significant expansion of the Company’s management team to support the business as it moves into clinical development of its ibuprofen TEPI Patch®.

David brings over 30 years’ experience in pharmaceutical and medical device product development, in both small and large pharmaceutical companies, as well as at a senior level in global contract research organisations. He has held a variety of development roles, most recently as Lead Consultant at DDPC Ltd for three years and prior to that as Chief Development Officer at Futura Medical plc, where he was responsible for growth and development of the product pipeline from ideation through to regulatory approvals. He was part of the senior management team that took the company through to its admission to AIM, helping to grow the company from angel investment to a market capitalisation of £50m. In his spare time David holds three voluntary directorships – with the clinical outsourcing trade association PCMG Ltd, the charity Ordinary 2 extraordinary Ltd, and with the Red Lion Group, a medical charity.

David Davies commented, “I am delighted to be joining Medherant at this exciting stage in the company’s growth and development. My previous experience, particularly working with topical gels at Futura Medical, will be useful in developing patch-based products at Medherant. I’m looking forward to working with the rest of the team to deliver value growth for our investors and novel, exciting and effective products for our customers.”

Sally Waterman, COO of Medherant, added, “We’re thrilled to welcome David to the Medherant team. His knowledge of all aspects of the drug development pathway, and his experience in developing internal and external teams to help deliver company growth, will be invaluable as Medherant moves to the next stage of its evolution.”

Medherant has completed non-clinical work on its lead product, ibuprofen TEPI Patch®, and is currently working with AdhexPharma to manufacture the product, ready for clinical trials.


For further information, contact:

Nigel Davis, CEO
T: +44 (0)24 7632 3060

Media Relations, Sciad Communications
Deborah Cockerill / Juliette Craggs
T: +44 (0)20 7470 8801

Notes for Editors

About Medherant
Medherant Ltd is a leading developer of next-generation transdermal drug delivery patches. The Company was founded by Professor David Haddleton and the University of Warwick in 2015.

Medherant has built upon its founders’ world-leading expertise in bio-adhesives and polymer chemistry to create adhesive drug delivery patches that overcome many of the limitations of patches currently on the market:

  • Its TEPI Patch® technology can be used with a wider range of drugs, including those that are not suitable for oral administration.
  • The amount of drug that can be loaded into the patch is greater, enabling the development of more effective transdermal therapies.
  • The TEPI Patch® contains a novel adhesive which will provide a better patient experience as the patch sticks to the skin for longer, is less painful to remove, and does not leave a mark on the skin.

Medherant is developing products containing proven drugs that it intends to license prior to commercialisation. The Company’s first product is an ibuprofen patch. Manufacture for clinical trials will take place at AdhexPharma in France.

Medherant also runs feasibility studies that give companies the opportunity to see the benefits of delivering their drugs using the TEPI Patch® technology. Medherant seeks partnerships with companies wishing to extend the commercial life of their products or those that have drugs that cannot be delivered orally at sufficient dosage.

Medherant is backed by Mercia Technologies PLC, a national investment group focused on the funding and scaling of innovative businesses with high growth potential from the UK regions.

For more information, please see

Got an innovation you need bringing to life?

We’d love to hear from you! Head to our contact page to start a conversation.

Photo of Esther Gibson